• news-banner

    Expert Insights

COVID-19: Advertising Responsibly

The ASA continues its drive to ensure responsible advertising during the COVID-19 pandemic.

At the outset of the pandemic the ASA took swift action to highlight to advertisers it would act quickly and robustly against ads that exploited people’s health related anxieties and the difficult financial or employment circumstances many people were facing. The ASA also published guidance on the main areas in which it believed ads may be deemed problematic. Despite this there have been a number of ads which have fallen foul of the CAP Code.

The latest series of problematic ads related to a vitamin C drink containing claims such as “Vitamin-C has been proven to boost immunity” which, taken in the midst of the pandemic, could be taken to imply that the drink could help to prevent, treat or cure COVID-19. Making such claims is not permitted unless the products in question are authorised on the EU Register of nutrition and health claims, which this product was not. It is also prohibited to make claims that food and supplements can prevent, treat or cure human disease. The ASA therefore held that the ads must not appear again.

Below we have outlined the ASA guidance and rulings since the beginning of the pandemic to highlight the main areas of concern which may have the potential to grossly undermine the UK’s response to the pandemic.

Key Areas of concern and ASA Rulings

1. Medicines and medical devices:

The key issue in this space is that ‘medical or medicinal claims’ can only be made for products where they are licenced medicines or appropriately marked medical devices.

ASA Rulings:

  • The ASA banned an ad which promoted an “Anti-Corona Virus Face Mask”.
  • The ASA banned a series of ads which promoted a “New Nano Tech Face Mask” and implied that the mask would offer protection against being infected by COVID-19.

2. Alternative and complementary therapies

The ASA made clear that it was likely to consider COVID-19 a condition for which medical supervision should be sought.

ASA Rulings:

  • The ASA banned advertising claims on websites and in social media made by three clinics offering IV drip treatments which made medicinal claims that implied they could prevent or treat COVID-19.

3. Food or food supplements

As seen above, the ASA made clear that ads that make health related claims and/or suggest a product may help protect consumers from infection of COIVD-19 by, for example, supporting their immune system, were likely to be viewed as problematic.

4. Fear, distress and social responsibility

The ASA highlighted that ads should not exploit an audience’s fear in order to mislead them into buying a product.

ASA Rulings:

  • The ASA banned an ad which stated “British Build, beds proudly made in the UK. No Nasty imports”. The ad also contained imagery whereby a cartoon mattress was wearing a green surgical mask. In the ASA’s view the ad was likely to cause serious or widespread offence as in combination with the image the reference to “nasty imports” was likely to be read as a negative reference to immigration or race.

Moving Forward

Ads in any of the special interest areas above will likely receive additional scrutiny from both the public and regulators. Advertisers must exercise special caution and be mindful of how ads may be perceived by the public in the current heightened state of awareness, especially if those ads contain health-related claims.
For more information on any of the ASA Rulings set out above, please use the following link

Our thinking

  • IBA Annual Conference 2025

    Simon Ridpath

    Events

  • Alumni Drinks Reception

    Events

  • London International Disputes Week: Trusts hurt: the fraud lawyer, the trust, and the avenues of attack (and defence)

    Tamasin Perkins

    Events

  • London International Disputes Week: Navigating International M&A Disputes: Insights and Strategies for 2025

    Stephen Burns

    Events

  • Maximising flexibility through subletting – key considerations for office occupiers

    Pippa Clifford

    Insights

  • People Management quotes Owen Chan on the UK government's plans to raise English language requirements on migrants

    Owen Chan

    In the Press

  • The Law Commission: Modernising Wills Law Report - a disputes perspective

    Lydia Kember

    Quick Reads

  • Retrospectively changing Indefinite Leave to Remain rules for those currently on the 5 year route to a 10 year route is unlawful and unfair

    Paul McCarthy

    Quick Reads

  • World Intellectual Property Review quotes Olivia Gray on the post-Brexit treatment of design rights

    Olivia Gray

    In the Press

  • Charles Russell Speechlys advises the shareholders of Stow Healthcare Group Limited on the sale of the company to CGEN Care Group

    David Coates

    News

  • Relief from Forfeiture: A recent High Court decision serves as reminder of key principles

    Andrew Ross

    Insights

  • The Lawyer cites our Firm in a podcast on AI and Innovation in the legal sector

    Joe Cohen

    In the Press

  • Bloomberg quotes Dominic Lawrance on the appeal of Italy for non-dom individuals considering relocating from the UK

    Dominic Lawrance

    In the Press

  • The FCA's PS25/4: Extending Investment Research Payment Optionality to Fund Managers

    Charlotte Hill

    Insights

  • Unravelling the Global Single Family Offices Tapestry

    James Carter

    Insights

  • Navigating IHT Concerns in Land Promotion: Hope Value and Some Innovative Solutions for Landowners and Developers

    Sam Jelley

    Quick Reads

  • A Boost for Water Quality? The Pickering Case 2025

    Kevin Gibbs

    Quick Reads

  • UK Immigration Reform – deeper restrictions on the horizon

    Paul McCarthy

    Quick Reads

  • The Court of Arbitration for Sport Appeals Procedure

    Benoît Pasquier

    Insights

  • Caroline Greenwell and Bella Henry write for Law 360 on the Santander fraud ruling and what it means for the UK banking sector

    Caroline Greenwell

    In the Press

Back to top